The Evidence

Can brain retraining cure MCS?

Brain retraining is not an established treatment for MCS. Controlled MCS trials have not shown reliable reversal of the illness or restoration of chemical tolerance. Some people report substantial benefit, and those reports deserve study, but improvement in fear, coping, sleep, illness perception, or function must not be relabeled as proof that MCS was caused—or cured—by thought.

Some people report major improvement after brain-based programs. Those reports deserve study, but they do not override the controlled MCS evidence: brain retraining has not been shown to reverse the illness or reliably restore chemical tolerance.

Brain retraining is one of the most emotionally charged subjects in the MCS community.

Some people describe dramatic improvement after programs built around neuroplasticity, mindfulness, somatic tracking, calming the nervous system, changing threat responses or repeatedly practicing new mental patterns. Other people spend months doing the same kinds of work and remain just as chemically reactive as before.

Those two experiences do not have to cancel each other out.

The scientific question is narrower: what has brain retraining actually been shown to change in people with MCS?

What we know

“Brain retraining” is not one standardized treatment. The term is used for very different approaches: mindfulness-based cognitive therapy, DNRS, the Gupta/Amygdala and Insula Retraining program, somatic tracking, Pain Reprocessing Therapy-inspired techniques, CBT, meditation, breath work, emotional-processing approaches and other nervous-system regulation programs.

These methods can target different outcomes. Some reduce distress. Some improve coping. Some may alter attention or fear. Some people report fewer symptoms or greater function. None of those outcomes is automatically the same as restored tolerance to a chemical exposure that previously produced a reproducible MCS reaction.

That distinction is the foundation of our approach: whenever we say a brain-based method “helps,” we name what improved.

What the evidence shows

The strongest MCS-specific randomized trial did not reverse MCS

The best controlled MCS test of a mind-body approach did not improve the illness itself. The most informative trial randomized 69 people to mindfulness-based cognitive therapy or treatment as usual and followed them through 12 months. The primary outcome was the QEESI, which measures symptoms, reactions after chemical exposures, and impact on daily life.

The result was clear: MBCT did not improve the primary MCS outcome. It also did not reduce depression or anxiety. It did, however, produce positive changes in illness perceptions that persisted through follow-up.

That matters because it separates two things that are often blurred together. The way people understood and emotionally represented their illness changed. Their overall MCS illness status did not.

The earlier randomized pilot told a similar story

A 2012 pilot randomized 37 adults with MCS to an eight-week MBCT program or control condition. There were no significant between-group differences in the measured outcomes. Participants who completed the program nevertheless often said they benefited through better coping and sleep.

Again, those are legitimate outcomes. They are not evidence that chemical sensitivity itself was cured.

What about the widely repeated Gupta “85%” number?

A 2023 study of Amygdala and Insula Retraining included 53 participants who identified MCS among several chronic-condition subgroups. The MCS subgroup showed an 85 percent increase in retrospective self-rated overall health and functioning after using the program.

That number should not be described as “85 percent of MCS patients recovered,” “an 85 percent cure rate,” or evidence from a randomized MCS trial. The study was cross-sectional, recruited people from the Gupta Program customer database, relied on participants recalling their health before the program, had no MCS control group, and used self-reported overall health and functioning rather than verified restoration of chemical tolerance. The author also disclosed that her research-consulting company provided paid consulting services to the Gupta Program.

The study is still worth knowing about. It documents a group of program users who reported substantial improvement. What it cannot establish is causality, representativeness, the mechanism of improvement, or whether consensus-defined MCS reactions to previously reproducible triggers disappeared.

Evidence from other illnesses cannot automatically be converted into MCS evidence

Neuroplasticity-based approaches have stronger randomized evidence in some chronic-pain populations and have been studied in other chronic conditions. That is scientifically interesting and gives us hypotheses to test. It does not mean the same mechanism “defaults” to MCS.

MCS should be tested directly, with MCS outcomes.

The five-person n-butanol study does not rescue the treatment claim

The 2026 five-person n-butanol paper does not provide treatment evidence for MCS and should not be used to support exposure-based retraining. It had no randomized control group, no sham treatment, no blinded intervention, primarily subjective outcomes, and no meaningful control over participants’ changing real-world chemical exposures between sessions. It observed lower reported symptoms to one trained odorant; it did not establish treatment efficacy or generalized restoration of chemical tolerance.

One case report cannot turn mcs into a phobia

Millions of people report medically diagnosed MCS. One 2026 case report describes one older adult treated under a specific-phobia formulation after a toxic inhalation. Its own authors say the case cannot establish a causal treatment effect. It therefore cannot establish that MCS is a phobia, that CBT or graded exposure treats MCS generally, or that a phobia model explains consensus-defined MCS. One patient is not a population. A working phobia formulation for one patient is not a disease definition for millions of people.

What the registry is answering

This is one argument the Canary Registry can turn into measurement.

For every person who has tried a formal retraining or nervous-system program, the registry should record the program, duration and adherence, then separate outcomes: fear, coping, sleep, illness perception, symptom intensity, ability to function, and actual tolerance of previously reproducible environmental triggers.

If tolerance improved, we need to know which trigger, by how much, how it was tested, how long the improvement lasted, and whether relapse occurred.

Just as important, the registry should ask what else changed at the same time: housing, mold or water-damage exposure, occupational exposure, overall chemical load, diet, medications, infection, sleep, stress or other treatment. That control question is what begins turning a testimonial into usable data.

Where we stand

Some people report substantial improvement after brain-retraining approaches. Their experiences are real and deserve to be studied.

Exposure vigilance should not be pathologized as the cause

People who have repeatedly been made ill by unpredictable exposures often become more watchful of environments, products, odors, traffic, and buildings. That exposure vigilance can be a consequence of repeated physical reactions. It should not be converted into proof that fear or attention created the original disease.

If nervous-system work reduces fear, distress, or autonomic amplification, name that outcome. If it restores reproducible chemical tolerance, that must be demonstrated separately.

But those reports do not establish what caused their illness, whether their condition met established MCS criteria, whether retraining itself caused the improvement, or how representative responders are of people who meet established MCS criteria.

Published controlled evidence has not shown brain retraining to reverse MCS or reliably restore chemical tolerance. We therefore do not present brain retraining as a treatment for the underlying cause of MCS or as a substitute for reducing exposures that repeatedly make a person ill.

Calming the nervous system can still be valuable. If it improves fear, coping, sleep, illness perception, symptom intensity or function, say exactly that. If future studies show restored chemical tolerance, say that too.

We followed the evidence. Here’s where it leads →

Sources

Sources

1Hauge CR, Rasmussen A, Piet J, et al. Mindfulness-based cognitive therapy for multiple chemical sensitivity: a randomised controlled trial with 1 year follow-up. Journal of Psychosomatic Research. 2015;79(6):628–634. PMID: 26311155.
2Skovbjerg S, Hauge CR, Rasmussen A, Winkel P, Elberling J. Mindfulness-based cognitive therapy to treat multiple chemical sensitivities: a randomized pilot trial. Scandinavian Journal of Psychology. 2012. PMID: 22530938.
3Guenter D et al. Neuroplasticity-based treatment for fibromyalgia, chronic fatigue and MCS: feasibility and outcomes. Conference presentation, 2019.
4Gupta program MCS page and audit claim, guptaprogram.com/treatment-for/mcs/, captured 11 Sep 2026.
5Toussaint L et al. AIR randomized trial in Long COVID fatigue, 2023; Sanabria-Mazo JP et al. MAIR pilot RCT in fibromyalgia, J Clin Med 2020 — neither in MCS.
63. Bratty AJ. Neuroplasticity Intervention, Amygdala and Insula Retraining (AIR), Significantly Improves Overall Health and Functioning Across Various Chronic Conditions. Integr Med (Encinitas). 2023;22(6):20-28. PMID: 38404605. Source
74. Exposure-Based Treatment of Chemical Intolerance – A Multiple Case Study. Hygiene and Environmental Health Advances. Online 29 July 2026. Source
8Steinemann A. National Prevalence and Effects of Multiple Chemical Sensitivities. J Occup Environ Med. 2018;60(3):e152-e156. PMID: 29329146.
← Back to MCSDisability.com
↑